Biopharmx Corp (NYSEAMERICAN:BPMX)’s share price traded down 7.1% during mid-day trading on Friday . The stock traded as low as $0.34 and last traded at $0.39, 1,229,798 shares traded hands during trading. An increase of 127% from the average session volume of 542,438 shares. The stock had previously closed at $0.42.
Separately, Maxim Group set a $1.00 target price on shares of Biopharmx and gave the company a “buy” rating in a research report on Monday, September 9th.
The firm’s 50-day moving average price is $0.35 and its two-hundred day moving average price is $0.51.
An institutional investor recently bought a new position in Biopharmx stock. Barclays PLC bought a new stake in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 175,000 shares of the biotechnology company’s stock, valued at approximately $58,000. Barclays PLC owned about 1.23% of Biopharmx as of its most recent SEC filing.
About Biopharmx (NYSEAMERICAN:BPMX)
BioPharmX Corporation, a specialty pharmaceutical company, develops and commercializes novel prescription and over-the-counter (OTC) products that address dermatology and women's health markets. The company offers VI2OLET, an OTC molecular iodine dietary supplement that addresses cyclic breast discomfort, as well as alleviates the symptoms of fibrocystic breast condition (FBC).
Recommended Story: Investing in Blue-Chip Stocks
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.